Skip to main content Back to Top
Advertisement

9/12/2019

Ceftazidime Injection

Products Affected - Description

    • Fortaz powder for solution for injection, Teligent, 1 gram, TwistVials 25 count, NDC 24987-0434-00 - discontinued
    • Fortaz powder for solution for injection, Teligent, 2 gram, TwistVials 10 count, NDC 24987-0435-00 - discontinued
    • Tazicef powder for solution for injection, Pfizer, 1 gram, vial, 25 count, NDC 00409-5082-16
    • Tazicef powder for solution for injection, Pfizer, 6 gram, vial, 6 count, NDC 00409-5086-11
    • Ceftazidime powder for solution for injection, Sagent, 1 gram, vial, 25 count, NDC 25021-0127-20
    • Ceftazidime powder for solution for injection, Sagent, 2 gram, vial, 10 count, NDC 25021-0128-50
    • Ceftazidime powder for solution for injection, Sagent, 6 gram, vial, 6 count, NDC 25021-0129-99

Reason for the Shortage

    • Pfizer has Tazicef available.
    • Sagent has ceftazidime injection on shortage due to increased demand and manufacturing delays.
    • BBraun had ceftazidime on allocation due to increased demand.
    • Teligent discontinued Fortaz 2 gram vials, 6 gram vials, and both 1 gram/50 mL and 2 gram/50 mL premixes in February 2018. They also discontinued the 1 gram and 2 gram Twistvials in April 2019. The Fortaz 500 mg and 1 gram vials are on back order due to manufacturing delays.
    • WG Critical Care has ceftazidime available.

Available Products

    • Fortaz powder for solution for injection, Teligent, 1 gram, vial, 10 count, NDC 24987-0378-10
    • Fortaz powder for solution for injection, Teligent, 500 mg, vial, 10 count, NDC 24987-0377-10
    • Tazicef powder for solution for injection, Pfizer, 1 gram, ADD-Vantage vial, 25 count, NDC 00409-5092-16
    • Tazicef powder for solution for injection, Pfizer, 2 gram, ADD-Vantage vial, 10 count, NDC 00409-5093-11
    • Tazicef powder for solution for injection, Pfizer, 2 gram, vial, 10 count, NDC 00409-5084-11
    • Ceftazidime injection, BBraun, 1 gram/50 mL, premixed bag, 24 count, NDC 00264-3143-11
    • Ceftazidime injection, BBraun, 2 gram/50 mL, premixed bag, 24 count, NDC 00264-3145-11
    • Ceftazidime powder for solution for injection, WG Critical Care, 1 gram, vial, 25 count, NDC 44567-0235-25
    • Ceftazidime powder for solution for injection, WG Critical Care, 2 gram, vial, 10 count, NDC 44567-0236-10
    • Ceftazidime powder for solution for injection, WG Critical Care, 6 gram, vial, 6 count, NDC 44567-0237-06

Estimated Resupply Dates

    • Pfizer has Tazicef 1 gram vials on back order and the company estimates a release date of September 2019. The 6 gram fliptop vials are available in limited supply with a short expiration dating (December 2019).
    • Sagent has ceftazidime 2 gram and 6 gram vials on back order and the company estimates a release date of September 2019. The 1 gram vials are available with short expiration dating (December 2019).

Updated

Updated September 12, 2019 by Anthony Trovato, PharmD, BCPS. Created November 29, 2011 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins